• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
75,273.45 1,205.00
( 1.63%)
Global Indices
Nasdaq
46,438.76 293.69
(0.64%)
Dow Jones
6,611.15 33.78
(0.51%)
Hang Seng
53,715.15 1,462.87
(2.80%)
Nikkei 225
10,078.37 113.21
(1.14%)
Forex
USD-INR
93.79 0.26
(0.28%)
EUR-INR
108.70 0.48
(0.44%)
GBP-INR
125.65 0.64
(0.51%)
JPY-INR
0.59 0.00
(0.41%)

EQUITY - MARKET SCREENER

Marico Ltd
Industry :  Solvent Extraction
BSE Code
ISIN Demat
Book Value()
531642
INE196A01026
38.9849685
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
MARICO
50.51
97899.61
EPS(TTM)
Face Value()
Div & Yield %
14.93
1
1.38
 

Aurobindo Pharma arm receives 4 observations after US FDA inspection
Feb 28,2026
The facility (Unit-I), located at Kolthur Village, Shameerpet Mandal, Ranga Reddy, Telangana, was inspected from 16 February to 27 February 2026, and the inspection concluded with four observations. The company said it will respond to the US FDA within the stipulated timelines.

The company confirmed there is no impact on its financials or operations due to the inspection. Aurobindo Pharma stated its commitment to maintaining high-quality manufacturing standards across all its facilities worldwide and said it will update the stock exchanges if there is any further information.

Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The company’s consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.

Shares of Aurobindo Pharma shed 0.04% to end at Rs 1,221.55 on the BSE on Friday.